

REFERENCES

- Aithal GP, Day CP, Kesteven PJL, et al. 1999. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirements and risk of bleeding complications. *Lancet*, vol. 353, pp 717 – 719.
- Bajoria R, Sooranna SR, Contractor SF. 1996. Differential binding of warfarin to maternal, foetal and non-pregnant sera and its clinical implications. *J Pharm Pharmacol*, vol. 48, pp 486 – 491.
- Briggs GG, Freeman RK, Yaffe SJ (ed). 2002a. Amiodarone. In: *Drugs in pregnancy and lactation (6th ed)*. Philadelphia: Lippincott Williams and Wilkins, pp 52 - 59.
- Briggs GG, Freeman RK, Yaffe SJ (ed). 2002b. Captopril. In: *Drugs in pregnancy and lactation (6th ed)*. Philadelphia: Lippincott Williams and Wilkins, pp 174 - 180.
- Briggs GG, Freeman RK, Yaffe SJ (ed). 2002c. Carbamazepine. In: *Drugs in pregnancy and lactation (6th ed)*. Philadelphia: Lippincott Williams and Wilkins, pp 180-189.
- Briggs GG, Freeman RK, Yaffe SJ (ed). 2002d. Phenytoin. In: *Drugs in pregnancy and lactation (6th ed)*. Philadelphia: Lippincott Williams and Wilkins, pp 1116 - 1127.
- Brooks C, Rutherford JM, Gould J, et al. 2002. Warfarin dosage in postpartum women: a case-control study. *BJOG*, vol. 109, pp 187 – 190.
- Chan WS, Anand S, Ginsberg JS. 2000. Anticoagulation of pregnant women with mechanical heart valves. *Arch Intern Med*, vol. 160, pp 191 – 196.
- Cotrufo M, De Feo M, De Santo LS et al. 2002. Risk of warfarin during pregnancy with mechanical valve prosthesis. *Obstet Gynecol*, vol. 99, pp 35 – 40.
- Dickmann LJ, Rettie AE, Kneller MB, et al. 2001. Identification and functional characterization of a new CYP2 variant (CYP2C9*5) expressed among African Americans. *Mol Pharmacol*, vol. 60, pp 382 – 387.

- Franco B, Meroni G, Parenti G, et al. 1995. A cluster of sulfatase genes on Xp22.3: Mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. *Cell*, vol. 81, pp 15 – 25.
- Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, et al. 2003. Comparison of the quality of oral anticoagulation therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. *Arch Intern Med*, vol. 163, pp 2639 – 2646.
- Gadisseur AP, Kaptein AA, Breukink-Engbers WG, et al. 2004. Patient self-management of oral anticoagulation care vs. management by specialized anticoagulation clinics: positive effect on quality of life. *J Thromb Haemost*, vol. 2, pp 584 - 591.
- Ginsberg JS, Greer I, Hirsh J. 2001. Use of antithrombotic agents during pregnancy. *Chest*, vol.119, 122S – 131S.
- Gorlin RJ, Cohen MM, Hennekam RCM (ed). 2001. Teratogenic Agents. In: *Syndromes of the head and neck (4th ed)*. Oxford: Oxford University Press, pp 31 – 34.
- Hall JG, Pauli RM, Wilson KM. 1980. Maternal and fetal sequelae of anticoagulation during pregnancy. *Am J Med*, vol. 68, pp 122 – 138.
- Hall DR, Olivier J, Rossouw GJ, et al. 2001. Pregnancy outcomes in women with prosthetic heart valves. *J Obstet Gynecol*, vol. 21, pp 149 – 153.
- Higashi MK, Veenstra DL, Kondo LM, et al. 2002. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA*, vol. 287, pp 1690 – 1698.
- Hirsh J, Puster V, Ansell J, et al. 2003. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. *J Am Coll Cardiol*, vol.41, pp 1633 – 1652.

- Horstkotte D, Piper C. 2004. Improvement of oral anticoagulation therapy by INR self-management. *J Heart Valve Dis*, vol. 13, pp 335 - 338.
- Lafata JE, Martin SA, Kaatz S, et al. 2000. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis. *J Thromb Thrombolysis*, vol. 9, Suppl 1: S13 - 19.
- Lip GYH, Kamath S, Jafri M, et al. 2002. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulant therapy. *Stroke*, vol. 33, pp 238 – 244.
- Menger H, Lin AE, Toriello HV, et al. 1997. Vitamin K deficiency embryopathy: a phenocopy of warfarin embryopathy due to a disorder of embryonic vitamin k metabolism. *Am J Med Genet*, vol. 72, pp 129 – 134.
- Nadar S, Begum N, Kaur B, et al. 2003. Patients' understanding of anticoagulant therapy in a multiethnic population. *J R Soc Med*, vol. 96, pp 175 – 179.
- Pauli RM, Lian JB, Mosher DF, et al. 1987. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. *Am J Hum Genet*, vol. 41, pp 566 – 583.
- Sadler I, McCowan L, White H, et al. 2000. Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. *BJOG*, vol. 107, pp 245 – 253.
- Sareli P, England MJ, Berk MR, et al. 1989. Maternal and fetal sequelae of anticoagulation during pregnancy in patients with mechanical heart valve prostheses. *Am J Cardiol*, vol. 63, pp 1462 – 1465.
- Schardein JL (ed). 2000. Drugs affecting blood. In: *Chemically induced birth defects (3rd ed)*. New York: Marcel Dekker, pp 121 – 137.

Van Driel D, Wesseling J, Sauer PJJ, et al. 2002. Teratogen update: fetal effects after in utero exposure to coumarins. Overview of cases, follow-up findings, and pathogenesis. *Teratology*, vol. 66, pp 127 – 140.

Warkany J. 1976. Warfarin embryopathy. *Teratology*, vol. 14, pp 205 - 209.